Updated: This article has been refreshed to clarify Tom Steyer’s connection to Farallon Capital, replace outdated financial figures, and add newer context around Natera’s revenue growth, reimbursement momentum, regulatory backdrop, and valuation risks.
Billionaire Tom Steyer Backs Natera Inc. as a High-Growth Stock Opportunity
Natera Inc. (NASDAQ: NTRA) remains one of the more closely watched growth stories in genetic testing, but investors should be precise about the “Tom Steyer” angle. Farallon Capital Management — the investment firm Steyer founded in 1986 but no longer runs day to day — disclosed a large Natera position in 2024 regulatory filings. That purchase drew attention because Farallon is known for deep fundamental research and concentrated positions in companies with long runway potential.
Natera specializes in cell-free DNA testing across three core markets: women’s health, oncology, and organ health. Its best-known products include Panorama, a noninvasive prenatal screening test; Horizon, a carrier screening test; Prospera, used in transplant monitoring; and Signatera, a personalized minimal residual disease (MRD) test designed to detect molecular traces of cancer after treatment.
The company’s growth thesis has increasingly centered on Signatera. Oncologists are using MRD testing to monitor recurrence risk, guide follow-up care, and evaluate treatment response. That puts Natera in the middle of a fast-expanding precision oncology market where testing volumes, clinical evidence, and payer coverage can reinforce one another over time.
Natera’s addressable market is often described by analysts as tens of billions of dollars across oncology, reproductive health, and transplant testing. But the key debate for investors is no longer whether demand exists. It is whether Natera can scale profitably while defending its lead against diagnostics rivals, payer scrutiny, and rapidly evolving clinical standards.
Farallon’s involvement helped place Natera on the radar for growth-focused funds, but it should not be treated as a direct endorsement from Steyer himself. The more important takeaway is that institutional investors have been willing to underwrite Natera’s long-term market opportunity despite a history of losses and high operating spending.
How Tom Steyer’s Investment Could Impact Natera’s Market Position and Stock Performance
The original 2024 disclosure came at a time when Natera was already gaining momentum. Since then, the stock has benefited from a broader re-rating tied to stronger test volumes, improving gross margins, and repeated evidence that oncology is becoming a larger part of the business mix.
Natera’s financial profile has improved meaningfully from the earlier R&D-heavy phase. In 2024, the company reported full-year revenue of roughly $1.7 billion, up sharply from the prior year, driven by higher test volumes and better average selling prices. Management also delivered better margin performance as the company scaled its lab operations and increased the contribution from oncology testing.
That said, Natera is still not a low-risk diagnostics stock. The company has historically reported net losses, and investors remain focused on when revenue growth will translate into consistent operating profitability and cash generation. The bull case depends on operating leverage: as testing volumes rise, fixed lab and commercial costs should be spread across a larger revenue base. The bear case is that competition, reimbursement pressure, legal costs, or continued sales investment could delay that margin inflection.
Reimbursement remains one of the most important variables. Natera has secured Medicare coverage for multiple Signatera use cases, and private payer adoption has expanded over time. In diagnostics, coverage decisions can be just as important as clinical adoption because physicians are more likely to order tests when payment pathways are clear. Continued payer wins would strengthen Natera’s competitive position; any reimbursement cuts or adverse coverage changes could pressure revenue and investor sentiment.
Competition is also intensifying. Guardant Health, Exact Sciences, Tempus AI, and other molecular diagnostics companies are pursuing opportunities in cancer screening, recurrence monitoring, and treatment selection. Natera’s advantage is its large installed base, substantial clinical data, and early traction in personalized MRD testing. But rivals are well funded, and the market is large enough that leadership may shift by cancer type, test use case, and payer channel.
Another important update is the regulatory backdrop for laboratory-developed tests. The FDA finalized a rule in 2024 that would have increased oversight of lab-developed tests, creating uncertainty for companies like Natera. A federal court later vacated that rule in 2025, reducing near-term regulatory pressure. Even so, investors should not assume the issue is permanently settled. Diagnostics regulation remains politically and legally fluid, and future FDA, congressional, or court action could reshape compliance requirements.
The “Steyer effect” may have helped attract attention, but Natera’s stock performance now depends less on who owns the shares and more on execution. The company has become a more established growth name, which means expectations are higher. Strong quarterly results can support the premium valuation, while even modest disappointments in volume growth, margins, or guidance could trigger volatility.
Future Outlook: What Investors Should Watch Following Steyer’s Endorsement of Natera
Natera’s next phase is about proving that its testing platform can become not just large, but sustainably profitable. Investors should watch four areas closely: oncology volume growth, reimbursement expansion, margin improvement, and competitive positioning.
First, Signatera adoption remains the biggest swing factor. If MRD testing continues moving deeper into standard oncology practice, Natera could see durable growth for years. The most important signals will be test volume growth, new clinical data, additional guideline inclusion, and broader usage across cancer types beyond colorectal cancer.
Second, payer coverage needs to keep improving. Medicare coverage has helped validate the market, but commercial payer adoption is essential for long-term scale. Investors should pay attention to updates on covered lives, average selling prices, denial rates, and management commentary on reimbursement stability.
Third, margins must continue moving in the right direction. Natera has already shown better gross margin performance as volumes have grown, but the market wants evidence that operating expenses can grow more slowly than revenue. Sales and marketing spending is necessary to build adoption, especially in oncology, but investors will increasingly expect discipline as the company matures.
Fourth, the balance between growth and valuation matters. Natera’s stronger execution has made the stock less of an undiscovered opportunity and more of a premium growth holding. That can be justified if revenue growth remains high and profitability improves, but it also raises the risk of sharp pullbacks if results fall short.
Investors should also monitor legal and competitive developments. The diagnostics industry has seen frequent patent disputes, false-advertising claims, and challenges around clinical utility. Any major litigation outcome involving Natera or a close competitor could affect market perception, even if the underlying business remains strong.
Farallon’s reported stake was an important signal in 2024, but it should be viewed as part of a broader institutional shift toward companies with exposure to precision medicine. The more durable story is that Natera has built one of the strongest commercial platforms in genetic testing and is trying to convert that lead into long-term earnings power.
Bottom line: Natera remains a compelling but high-expectation growth stock. The company has stronger revenue momentum and a clearer path to operating leverage than it did when Farallon’s position first attracted attention. Still, investors should treat the billionaire-linked narrative as secondary. The real test is whether Natera can keep expanding Signatera adoption, protect reimbursement, improve margins, and withstand competition in one of the most important growth markets in diagnostics.
⚠️ Disclaimer: This article is for informational purposes only and does not constitute financial advice. Always do your own research before making investment decisions.
The Bottom Line
- Farallon Capital’s Natera stake drew attention, but Tom Steyer founded the firm and is not its current day-to-day portfolio manager.
- Natera’s growth story is increasingly driven by Signatera and the expanding market for MRD testing in oncology.
- Revenue and margins have improved since 2024, but valuation, reimbursement, competition, and profitability remain key risks for investors.
